SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Medical - Drugs >

Spectrum Pharmaceutecals, Inc. (SPPI)

SPPI RSS Feed
Add SPPI Price Alert      Hide Sticky   Hide Intro
Moderator: Ville, antihama
Search This Board: 
Last Post: 12/12/2017 8:22:35 PM - Followers: 78 - Board type: Free - Posts Today: 0

http://www.spectrumpharm.com/

- Spectrum Pharmaceuticals Highlights Poziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) Presented at the 18th IASLC World Conference on Lung Cancer in Japan  - PR

http://investor.sppirx.com/releasedetail.cfm?ReleaseID=1044288
 

- 18th IASLC World Conference on Lung Cancer: Poziotinib Update - Conference Call 

https://edge.media-server.com/m6/p/4r5me9dd

.  

 

SureTrader
Interactive Brokers Advertisement
SPPI
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SPPI News: Spectrum Pharmaceuticals Highlights 15 Abstracts at the 59th Annual Meeting of the American Society of Hematology (ASH) in At... 12/04/2017 07:00:00 AM
SPPI News: Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2017 London Healthcare Conference on November 15th 11/08/2017 07:00:00 AM
SPPI News: Quarterly Report (10-q) 11/03/2017 04:23:21 PM
SPPI News: Current Report Filing (8-k) 11/02/2017 04:07:08 PM
SPPI News: Spectrum Pharmaceuticals Reports Third Quarter 2017 Financial Results and Pipeline Update 11/02/2017 04:02:00 PM
PostSubject
#1973   About neratinib and "other" HER2-targeting therapies. antihama 12/12/17 08:22:35 PM
#1972   antihama you may be right. The real meat Ville 12/11/17 11:10:52 AM
#1971   They didn't have tests for these mutations not antihama 12/08/17 05:18:12 PM
#1970   I hope that comes to fruition Ville! Then antihama 12/08/17 04:52:24 PM
#1969   I’m with you on the waiting game. SPPI Bull 12/08/17 04:33:47 PM
#1968   boring times! Ville 12/08/17 01:57:55 PM
#1967   IASLC Atlas of EGFR Testing in Lung Cancer antihama 12/07/17 04:35:16 PM
#1966   BlackRock beneficially owns 10% or more of Spectrum antihama 12/06/17 02:21:08 PM
#1965   RE: Spectrum equity stake in CASI antihama 12/06/17 02:05:18 PM
#1964   More on the genetic testing Foundation Medicine gets antihama 12/01/17 07:49:07 PM
#1963   Actually reading Gottlieb's remarks to Congress, I don't antihama 12/01/17 03:05:20 PM
#1962   Interesting positive stuff happening w the FDA antihama 12/01/17 12:17:06 PM
#1961   New Randomized Romidepsin vs Romidepsin/Pralatrexate RR PTCL P3 antihama 11/29/17 06:02:50 PM
#1960   Article on biotechs having good years mentions SPPI antihama 11/22/17 04:00:41 PM
#1959   more concrete news which is right around the antihama 11/22/17 07:40:00 AM
#1958   Surprisingly positive SPPI article from The Motley Fool! antihama 11/20/17 07:50:48 AM
#1957   This goes hand-in-hand IDing mutations across different cancers antihama 11/19/17 03:29:48 PM
#1956   I looked at it a little differently than antihama 11/19/17 09:46:57 AM
#1955   Exactly...until there is concrete data or FDA response SPPI Bull 11/17/17 05:11:41 PM
#1954   Nice bull trap yesterday... Ville 11/17/17 01:47:00 PM
#1953   Yeah, I did take notice the blip about antihama 11/17/17 08:43:28 AM
#1952   "So what do you attribute from the CC Ville 11/17/17 02:06:07 AM
#1951   chuckalo, there is a difference between "exon 20" Ville 11/17/17 01:57:50 AM
#1950   Perhaps HUGE, was not the right word to antihama 11/16/17 04:44:31 PM
#1949   VILLE. I know from reading your posts for Chuckalo 11/16/17 04:31:05 PM
#1948   I don't trust R.S. and I never will. Ville 11/16/17 02:45:49 PM
#1947   Ville. Your statement sounded harsh and contradictory. So Chuckalo 11/16/17 11:10:17 AM
#1946   exon 20 insertion mutations in other cancer types Ville 11/16/17 08:04:52 AM
#1945   2 Takeaways from today’s Jefferies London HCC (psst, antihama 11/15/17 08:14:05 PM
#1944   It was great- I sold out though but jtf3 11/15/17 06:00:19 PM
#1943   So jtf3, with a 4.57% rise (up 86c antihama 11/15/17 05:59:33 PM
#1942   I think your concerns are unwarranted like they antihama 11/13/17 02:13:05 PM
#1941   351a is the normal BLA process whereas 351k antihama 11/13/17 01:29:09 PM
#1940   A show of Smoke and Mirrors it is...and stugwins 11/13/17 12:02:20 PM
#1939   I would have to say 351a. Why? Well, Ville 11/13/17 10:51:54 AM
#1938   Rather, I should have worded it more clearSounds antihama 11/12/17 08:41:42 PM
#1937   Correct, I was looking at my notes from antihama 11/12/17 08:36:33 PM
#1936   OK, it's official in my book, 2 trials antihama 11/12/17 06:11:59 PM
#1935   Maybe the original PK study was done in Ville 11/12/17 10:03:43 AM
#1934   pK studies on a 351a pathway are usually stugwins 11/11/17 01:47:30 PM
#1933   351-a pathway. It is a new drug, no biosimilar! Ville 11/11/17 11:21:21 AM
#1932   Antihama, 505b2 is only for NDAs (i.e small stugwins 11/11/17 10:40:29 AM
#1931   Evolution of Rolontis clinical trial requirements for BLA. antihama 11/11/17 08:45:50 AM
#1930   stugwins, they are using the 505b2 pathway so, antihama 11/10/17 05:05:27 PM
#1929   Revising what I said about the Rolontis delay. antihama 11/10/17 04:34:37 PM
#1928   One relies on PK data to piggy back stugwins 11/10/17 02:51:56 PM
#1927   I get the impression you are not very Ville 11/10/17 12:30:31 PM
#1926   Oder? are you German? stugwins 11/10/17 12:21:49 PM
#1925   The PK study has a completion date of Ville 11/10/17 09:28:19 AM
#1924   Yes, I agree that needing 2 P3 studies antihama 11/09/17 06:11:54 PM
PostSubject